Re: " Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program."

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fuzzyjr

Rank: Vice President [?]

Points: 5268 [?]

Votes: 36 Score: 3.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: " Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program."

in response to

Re: " Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program."

KOO-KOO2

posted on May 09, 2022 09:13AM

"So meeting FDA in August 2022 for the CORAL Study Design can only mean that this "new" PH3, won't see the light of day until Q1 2023 if that. Not soon enough to stop the SPP from continuing its downward spiral."

I agree Koo.

This might explain the steady drip drip drip in our Sp & the setting of new 52 lows + the cheap PP that was done.Pre market looks weak as well.

4 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply